Tel Aviv Stock Exchange Ltd. · TASE:TASE
Tel Aviv Stock Exchange — Novolog Group — Q3 2020 Earnings Presentation
24 slides from Tel Aviv Stock Exchange's earnings presentation, November 2020
Slide 1: Novolog Group Presentation
Novolog Group Presentation November 2020
Slide 2: Forward-looking statement
Forward-looking statement • The information included in this presentation is a summary only and does not exhaust all of the information on the Company and its business, nor is it a substitute for inspection of the Periodic Report for 2020, the Company’s current reports and the presentations released
Slide 3: Business Card
Business Card ▪ Founded in 1966 ▪ Approximately 650 employees ▪ The Company was listed on the ▪ Strong and stable statement of Tel-Aviv Stock Exchange in financial position and no bank 2017 debt ▪ One of the leading companies in ▪ Dividend distribution policy – Israel in healthcare logistics 70% of
Slide 4: Strategy
Strategy Multinational companies in the pharmaceutical and medical device industries Addition and development Constant development of various services to make of services to drive healthcare products and down healthcare costs services accessible to customers at home HMOs, Hospitals, Patients Insuran
Slide 5: Business Development
Business Development 2019 Digital Health 1966 Health Care services Complex logistics, clinical trials Medicine distribution for multinational companies Novolog Group Presentation | November 2020
Slide 6: Group Structure
Group Structure Logistics Division Health Care Division Digital Health Division Providing complex logistics Providing medical services to Providing medical information services and supplementary patients in their homes and services to patients and pharmaceutical, medical device physicians and clinic
Slide 7: Health Care Services
Health Care Services The health care services division specializes in providing healthcare services to patients at home. We improve the treatment and service experience using state-of-the-art technology. The division provides services to healthcare organizations, insurance companies and multinationa
Slide 8: Logistics and related services
Logistics and related services Market leader in medical logistics and a strategic partner of international pharmaceutical companies and medical device companies Novolog - Specializes in storage, distribution and logistic services of and for the pharmaceutical and narcotics industries and operates a
Slide 9: Digital Health
Digital Health A leading platform of technological offerings for doctors and patients. We enable patients to search, book, and review medical specialists online. Our patient self-scheduling solutions help health systems expand patient access and acquisition Informed - Provides clinicians a strong on
Slide 10: Q3 2020 Highlights
Q3 2020 Highlights In October 2020, a transaction for the acquisition of 51% of the shares of Salus Ltd. was consummated. In September 2020, a dividend was paid to the company’s shareholders at the sum of ILS 12 million, as an advance on account of the annual dividend distribution for 2020. Th
Slide 11: Salus
Salus Salus is a medical center that works with a unique team of medical specialists who provide personalized medical services. All aspects of a patient’s medical care are managed at Salus by medical specialists who make home visits and carry out a variety of treatments and tests, including treatmen
Slide 12: Result Overview Q3 2020
Result Overview Q3 2020 Novolog Group Presentation | November 2020
Slide 13: Results including IFRS16 - Q3 2020
Results including IFRS16 Q3 2020 (ILS millions) Q3 2020 Q3 2019 % change Revenues 290.5 266.6 8.9% Gross Profit +38% Gross Profit 33.0 23.8 38.3% Operating Profit +652% Operating Profit 15.1 2.0 652.1% Net Profit (loss) 9.7 (3.7) 360.0% Adjusted EBITDA +34% Adjusted EBITDA (*) 28.0 20.9 33.9% (*) Ad
Slide 14: Results including IFRS16 - YTD 2020
Results including IFRS16 YTD 2020 (ILS millions) YTD 2020 YTD 2019 % change Revenues 859.9 779.0 10.4% Gross Profit +29% Gross Profit 93.2 72.5 28.5% Operating Profit +96% Operating Profit 46.7 23.8 95.9% Net Profit 32.2 4.4 626.0% Adjusted EBITDA +21% Adjusted EBITDA (*) 78.1 64.8 20.5% (*) Adjuste
Slide 15: Results excluding IFRS16 - Q3 2020
Results excluding IFRS16 Q3 2020 (ILS millions) Q3 2020 Q3 2019 % change Revenues 290.5 266.6 8.9% Gross Profit +43% Gross Profit 34.2 23.9 43.2% Operating Profit +760% Operating Profit 14.6 1.7 759.7% Net Profit (loss) 10.5 (2.8) 474.4% Adjusted EBITDA +45% Adjusted EBITDA (*) 22.8 15.7 45.2% (*) A
Slide 16: Results excluding IFRS16 - YTD 2020
Results excluding IFRS16 YTD 2020 (ILS millions) YTD 2020 YTD 2019 % change Revenues 859.9 779.0 10.4% Gross Profit +29% Gross Profit 93.6 72.5 29.2% Operating Profit +79% Operating Profit 40.7 22.8 78.7% Net Profit 31.1 7.5 312.8% Adjusted EBITDA +28% Adjusted EBITDA (*) 63.0 49.3 27.7% (*) Adjuste
Slide 17: Results by Segment excluding IFRS16 - Q3 2020
Results by Segment excluding IFRS16 Q3 2020 (ILS millions) Revenues Adjusted EBITDA Q3 2020 Q3 2019 % Q3 2020 Q3 2019 % Logistics 257.4 244.5 5% 15.6 10.9 43% Health Care 30.4 19.9 53% 5.4 3.6 49% Digital Health 5.5 3.5 60% 1.8 1.2 51% Intercompany Transactions )2.8( )1.3( - - Total 290.5 266.6 9% 2
Slide 18: Results by Segment excluding IFRS16 - YTD 2020
Results by Segment excluding IFRS16 YTD 2020 (ILS millions) Revenues Adjusted EBITDA YTD 2020 YTD 2019 % YTD 2020 YTD 2019 % Logistics 766.2 722.7 6% 40.2 35.8 12% Health Care 85.4 51.3 66% 17.3 9.9 74% Digital Health 16.7 9.2 81% 5.5 3.6 54% Intercompany Transactions )8.4( )4.2( - - Total 859.9 779
Slide 19: Balance Sheet including IFRS16
Balance Sheet including IFRS16 Q3 2020 (ILS millions) 30/09/2020 31/12/2019 Cash 187 185 Current assets 2,038 1,675 Cash ILS 187 million Non-current assets 467 475 Equity ILS 286 million Current liabilities 2,062 1,713 Non-current liabilities 157 173 Debt ILS 0.5 million Equity 286 264 Total Assets
Slide 20: 100 plan
100 plan before the impact of IFRS16 As part of our long-range growth plan, the Company's management estimates that by 2021, the adjusted EBITDA from current operations in Israel is expected to reach about ILS 100 million and the operating profit is expected to total ILS 64 million 100 ILS million I
Slide 21: Growth engines
Growth engines • Expanding Home Care services • Continued growth in Digital Health and Telemedicine activities • Growth in our activities with HMOs and hospitals • Developing additional SLAs with insurance companies • Medical cannabis activities • Acquisitions in Israel that support the Group's grow
Slide 22: Financial Executive Summary
Financial Executive Summary Strong financial Diversification Responsible Approach Capital allocation priorities performance The Company has a Future growth will be The Company is not Investing for consistent track record fueled by all three leveraged and invests continued growth of delivering strong
Slide 23: Capital Allocation Strategy For Growth
Capital Allocation Strategy For Growth Reinvest for growth Acquisitions Returns to our shareholders Investing in processes and ventures Acquisitions that support Dividend policy – that lead to organic growth and our current strategies 70% of the net profit generate higher profits Novolog Group Prese
Slide 24: Thanks
Thanks nNevelegq THE HEALTH CARE GROUP